Wuhan General Group (China), Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jeff Robinson
- Full Time Employees
- 700
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 401 Ryland St. Ste 200-A Cape Town NV South Africa 89502
- IPO Date
- Apr 19, 2006
- Website
- wuhn.org
- Similar Companies
- Business
- Wuhan General Group (China), Inc. (WUHN) is a nutraceutical biotechnology company that researches, develops, and commercializes cannabidiol (CBD)-based products under the Dr. AnnaRx brand for pharmacies, as well as alternative plant-based cannabinoids and psilocybin therapies targeting medical applications including cancer, mental disorders, chronic pain, alcohol dependency, anxiety, addiction, and cardiovascular conditions; it offers additional brands such as Anna, Medspresso, and Liviana encompassing CBD-infused foods, beverages, and mushroom-based nutraceuticals with 14 SKUs focused on premium consumer education and mental health research. The company operates through subsidiaries like MJ MedTech and Neurai Life Sciences, which employs artificial intelligence for drug discovery in mental health treatments, and maintains geographic presence in South Africa for retail distribution via over 100 independent stores in Cape Town, Canada for headquarters functions, and historical ties to China. Founded in 1988 as Riverside Capital, Inc. in Colorado and headquartered at 6500 Transcanada Highway, Pointe-Claire, Quebec H9R 0A5, Canada, it pivoted from industrial blowers via Wuhan Blower to biotechnology, reporting approximately 700 employees under CEO Jeffrey Robinson. Recent developments include expansion of Medspresso and Liviana brands to target 600 South African stores by late 2022, launch of Neurai Life Sciences for AI-driven therapies, introduction of sustainable Hempcelium packaging for Liviana olive oil, receipt of an acquisition offer for loss-making subsidiaries to settle creditor obligations amid legal issues, and participation in investor events like the 2022 Master Investor Show; no major updates reported post-2022 amid low trading activity on OTC Pink Sheets.
Head-To-Head Review: Xometry (NASDAQ:XMTR) versus Wuhan General Group (OTCMKTS:WUHN)
Financial Contrast: Middleby (NASDAQ:MIDD) vs. Wuhan General Group (OTCMKTS:WUHN)
Wuhan General Group (OTCMKTS:WUHN) vs. Standex International (NYSE:SXI) Head-To-Head Comparison
The Future Of Personalized Medicine For Mental Illness by Dr. Riyad Domingo
Medspresso Announces Additional Speciality Coffees To The Range
M2Bio Sciences Appoints Dr. Riyad Domingo as Chief Innovation Officer
Dr. AnnaRx(TM) Launching CBD & CBN Nutraceutical Line
Dr. Southey and Dr. Zarrebini Join M2Bio Sciences and Establish M2Bio Blockchain Research and Technology Group
Wuhan General Group Launches M2Bio Labs in Hout Bay, South Africa
Wuhan General Group Updates on Third Scientific Paper Published on Psychedelics
Wuhan Sciences Launches the M2Bio Surfboard NFT Collection
Wuhan General Group Appoints Robert "Black Tiger" Simbowe as Director of Health and Fitness
Wuhan General Group Appoints Michael Sachar CEO of M2Bio Sciences Food & Beverage
Liviana Artisanal CBD Olive Oils Have Arrived
Wuhan General Group Secures Lab for Hemp and Mycelium Eco-Friendly Research & Development
Wuhan General Group Recruiting in Lesotho for its Medicinal Cannabis Cultivation Facility
Medspresso(TM) Partners with CNC Products for Online Listing and CSR Activities
Wuhan General Group Introduces Liviana(TM) CBD Infused Artisanal Olive Oil
CORRECTION: Wuhan Launches Medspresso CBD Infused Whole Bean Roasted Coffee
Wuhan Launches Medspresso CBD Infused Whole Bean Roasted Coffee